Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

24,446 total articles

Eldorado Gold Announces First Concentrate Produced at McIlvenna Bay

Eldorado Gold Announces First Concentrate Produced at McIlvenna Bay

Eldorado Gold Corporation announced the production of the first copper concentrate at its 100%-owned McIlvenna Bay Project in Saskatchewan, Canada. This milestone marks a key step towards achieving commercial production targeted for Q3 2026. The project diversifies Eldorado's portfolio by adding copper and zinc exposure and enhances its Canadian op…

Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine

Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine

Eledon Pharmaceuticals announced updated data from an investigator-initiated trial at UChicago Medicine demonstrating that all 12 patients with Type 1 Diabetes undergoing islet transplantation achieved insulin independence and improved glycemic control using tegoprubart, a novel anti-CD40L antibody. The calcineurin inhibitor-free regimen showed exc…

Aclarion Stockholders Approve All Proposals at 2026 Annual Meeting

Aclarion Stockholders Approve All Proposals at 2026 Annual Meeting

Aclarion, Inc., a Nasdaq-listed healthcare technology company specializing in chronic low back pain diagnostics, announced that its stockholders approved all proposals at the 2026 Annual Meeting, including board member elections, auditor appointment, and equity plan amendments. The company reported 196% year-over-year growth in its Nociscan scan vo…

Concorde International Group Enters Exclusive Partnership with TrackerHero, Onboarding Its Business Model–Driven, Technology-Enabled Facilities Security Operations

Concorde International Group Enters Exclusive Partnership with TrackerHero, Onboarding Its Business Model–Driven, Technology-Enabled Facilities Security Operations

Concorde International Group Ltd. (NASDAQ: YOOV), a provider of technology-enabled security solutions, has entered into an exclusive strategic partnership with Malaysia-based TrackerHero to integrate TrackerHero's AI and IoT-powered digital patrol management system, THPatrol, into Concorde's facilities security operations in Singapore. The collabor…

Brady Corporation Announces CEO Transition

Brady Corporation Announces CEO Transition

Brady Corporation announced that Russell Shaller will retire after 11 years as CEO and board member, with Vineet Nargolwala appointed as the new CEO effective June 8, 2026. Nargolwala brings extensive experience in technology and public companies and will lead Brady through its major acquisition of Honeywell’s Productivity Solutions and Services bu…

EHang Announces US$30 Million Share Repurchase Program

EHang Announces US$30 Million Share Repurchase Program

EHang Holdings Limited, a leading advanced air mobility technology company listed on Nasdaq, announced a $30 million share repurchase program over the next 12 months. The company's board authorized buying back shares to demonstrate confidence in its long-term growth and value delivery to shareholders. The repurchase will be funded mainly from exist…

Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026

Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026

Upstream Bio announced that new data from its Phase 2 VIBRANT trial evaluating verekitug, a novel TSLP receptor antagonist monoclonal antibody, in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) will be presented at the EAACI 2026 Congress. Verekitug is uniquely positioned as the only antagonist targeting the TSLP receptor in clinic…

Quantum Cyber Signs LOI to Acquire an Estimated 43,000 Square Foot U.S.-Based Manufacturing Facility to Support Mass-Scale Autonomous Drone Production

Quantum Cyber Signs LOI to Acquire an Estimated 43,000 Square Foot U.S.-Based Manufacturing Facility to Support Mass-Scale Autonomous Drone Production

Quantum Cyber N.V., a Nasdaq-listed autonomous defense technology company, announced its wholly owned subsidiary Quantum Drones Corporation has signed a Letter of Intent to acquire a manufacturing facility in Bridgeport, Connecticut. The acquisition supports the company's strategic shift from technology licensing to vertically integrated manufactur…

Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)

Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)

Mineralys Therapeutics announced new late-breaking data from its Phase 2 and Phase 3 trials showing that lorundrostat, a selective aldosterone synthase inhibitor, modulates heart failure risk biomarkers in patients with uncontrolled hypertension. The data will be presented at the Endocrine Society's annual meeting, highlighting lorundrostat's effic…

Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. Lives

Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. Lives

Tonix Pharmaceuticals announced it has secured a second commercial payer agreement effective June 1, 2026, with a leading group purchasing organization (GPO), increasing commercial insurance coverage of its fibromyalgia drug TONMYA® to approximately 52 million U.S. lives. This milestone follows an earlier agreement and enhances patient access to th…

Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses

Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses

Kymera Therapeutics announced new preclinical data for KT-579, an oral IRF5 degrader showing disease-modifying effects in lupus models by targeting multiple inflammatory pathways. The ongoing Phase 1 trial in healthy volunteers aims to assess safety and biological activity, with results anticipated in the second half of 2026. Success could pave the…

Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer

Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer

Tango Therapeutics reported highly positive initial data from an ongoing Phase 1/2 clinical trial testing the combination of vopimetostat, a PRMT5 inhibitor, with daraxonrasib, a RAS(ON) inhibitor, in patients with second and third line MTAP-deleted and RAS-mutant metastatic pancreatic ductal adenocarcinoma (PDAC). The combination showed a 92% obje…

Devon Announces Results of Early Participation in Private Exchange Offers and Consent Solicitations and Extension of Deadline to Receive Total Exchange Consideration

Devon Announces Results of Early Participation in Private Exchange Offers and Consent Solicitations and Extension of Deadline to Receive Total Exchange Consideration

Devon Energy Corporation announced significant early participation in its exchange offers and consent solicitations related to outstanding notes issued by its subsidiary, Coterra Energy Inc. Eligible holders have tendered a high percentage of notes, and Coterra has received the necessary consents to adopt proposed amendments. The deadline to receiv…

SUNation Energy and Suniva Enter Definitive Merger Agreement, Creating a Platform for American Solar Manufacturing and Services Leadership

SUNation Energy and Suniva Enter Definitive Merger Agreement, Creating a Platform for American Solar Manufacturing and Services Leadership

SUNation Energy, Inc., a Nasdaq-listed solar energy provider, and Suniva, the largest U.S.-owned solar cell manufacturer, have entered into a definitive merger agreement to combine their operations under the Suniva name. The merger aims to accelerate U.S. solar cell manufacturing capacity expansion, enhance domestic supply chain resilience, and bro…

Genco Shipping & Trading Limited Announces Leading Proxy Advisor ISS Joins Glass Lewis and Egan-Jones in Recommending Shareholders Vote “FOR” ALL of Genco’s Director Nominees

Genco Shipping & Trading Limited Announces Leading Proxy Advisor ISS Joins Glass Lewis and Egan-Jones in Recommending Shareholders Vote “FOR” ALL of Genco’s Director Nominees

Genco Shipping & Trading Limited announced that top proxy advisory firms ISS, Glass Lewis, and Egan-Jones recommend shareholders vote for all of Genco's director nominees and against proposals from rival Diana Shipping Inc., amid an unsolicited tender offer dispute. The endorsements bolster Genco's board strategy and encourage shareholders to rejec…

Aeries Technology Reports Fiscal Year 2026 Results

Aeries Technology Reports Fiscal Year 2026 Results

Aeries Technology, Inc. announced fiscal year 2026 results with revenues of $70 million and net income of $3.5 million, a significant improvement from the previous year's losses. The company exceeded its adjusted EBITDA guidance and generated positive operating cash flow for the fourth consecutive quarter. It launched the AeriesOne A1 GCC Platform …

Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today

Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today

Artiva Biotherapeutics presented encouraging clinical data on AlloNK, their off-the-shelf NK cell therapy combined with rituximab, showing deep B-cell depletion and meaningful clinical responses in refractory rheumatoid arthritis (RA) and other autoimmune diseases at EULAR 2026. The FDA granted RMAT designation to AlloNK for refractory RA, supporti…

HP Recognized as a Leader in the 2026 Gartner® Magic Quadrant™ for Digital Employee Experience (DEX) Management Tools

HP Recognized as a Leader in the 2026 Gartner® Magic Quadrant™ for Digital Employee Experience (DEX) Management Tools

HP Inc. has been named a Leader in Gartner's 2026 Magic Quadrant for Digital Employee Experience (DEX) Management Tools. This recognition highlights HP's Workforce Experience Platform (WXP) for its comprehensive visibility, multi-vendor support, and AI-driven proactive management across devices and applications. HP emphasizes its strategic shift to…

Shattuck Labs Announces Phase 1 Results for SL-325

Shattuck Labs Announces Phase 1 Results for SL-325

Shattuck Labs announced positive Phase 1 trial results for SL-325, its lead monoclonal antibody targeting the DR3 receptor involved in inflammatory and immune-mediated diseases. The trial demonstrated favorable safety, durable receptor occupancy with complete TL1A blockade lasting over three months, and a low immunogenicity rate of 3.7%. The compan…

Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion

Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion

Lyell Immunopharma announced favorable safety data from its Phase 1 clinical trial of LYL273 in relapsed or refractory metastatic colorectal cancer, noting a significant reduction in severe gastrointestinal side effects through prophylaxis. The trial has been amended to a seamless Phase 1/2 design with expanded patient cohorts, including second-lin…

Lixiang Education Regains Compliance with Nasdaq Minimum Market Value of Publicly Held Shares Requirement

Lixiang Education Regains Compliance with Nasdaq Minimum Market Value of Publicly Held Shares Requirement

Lixiang Education Holding Co., Ltd., a private education services provider based in China, announced it has regained compliance with Nasdaq's minimum market value of publicly held shares requirement after its market value exceeded $5 million for ten consecutive business days ending June 4, 2026. This resolves a previous non-compliance issue noted i…

Pre-Feasibility Study for Grey Fox at Fox Complex — High Returns, Manageable Capital, Mine Life Extended to 2041

Pre-Feasibility Study for Grey Fox at Fox Complex — High Returns, Manageable Capital, Mine Life Extended to 2041

McEwen Inc. announced the results of the Pre-Feasibility Study (PFS) for its Grey Fox Project near Timmins, Ontario, extending the Fox Complex mine life to 2041 and projecting increased gold production. With an estimated initial capital expenditure of $181 million and robust economics assuming gold prices over $4,000/oz, the project is expected to …